Apr 22 |
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
|
Apr 18 |
Fate Therapeutics files to sell 3.64M shares for holders
|
Apr 6 |
Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress
|
Apr 3 |
Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
|
Mar 29 |
Why Is Amicus Therapeutics (FOLD) Down 8.1% Since Last Earnings Report?
|
Mar 28 |
Why Is Myriad (MYGN) Down 1% Since Last Earnings Report?
|
Mar 27 |
Fate Therapeutics (FATE) Down 8% Since Last Earnings Report: Can It Rebound?
|
Mar 19 |
Fate Therapeutics announces pricing of $100M underwritten offering and concurrent private placement
|
Mar 19 |
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
|
Mar 5 |
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
|